Related Experiment Video

Updated: Jan 24, 2026

Angiogenesis in the Ischemic Rat Lung
07:36

Angiogenesis in the Ischemic Rat Lung

Published on: February 8, 2013

15.9K

Emerging angiogenesis inhibitors for non-small cell lung cancer

Umberto Malapelle1, Antonio Rossi2

  • 1a Department of Public Health , University Federico II of Naples , Naples , Italy.

Expert Opinion on Emerging Drugs
|May 17, 2019
PubMed

Insights

Targeting angiogenesis, the process of new blood vessel formation, is vital for treating non-small-cell lung cancer (NSCLC). Anti-VEGF therapies show promise, and new inhibitors may restore antitumor immunity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Vascular Biology

Background:

  • Angiogenesis is essential for development and homeostasis, but its dysregulation drives cancer growth.
  • Targeting angiogenesis is a key strategy in cancer research and treatment, particularly for non-small-cell lung cancer (NSCLC).
  • Current anti-angiogenic therapies include monoclonal antibodies against VEGF and small molecules inhibiting tyrosine kinases.

Purpose of the Study:

  • To review the current state-of-the-art of anti-angiogenesis treatment in NSCLC.
  • To discuss emerging angiogenesis inhibitors and their potential in NSCLC management.
  • To explore the role of VEGF in tumor immunity and the potential of anti-angiogenic drugs in restoring antitumor responses.

Main Methods:

  • A structured literature search of bibliographic databases was conducted.
  • Peer-reviewed research and main conference meeting abstracts were reviewed.
  • A focused review question guided the literature search and discussion.

Main Results:

  • Anti-angiogenic strategies, including anti-VEGF therapies, have yielded positive results in NSCLC treatment.
  • VEGF exhibits immunosuppressive properties, suggesting anti-angiogenic inhibitors could enhance antitumor immunity.
  • New anti-angiogenic drugs with predictive biomarkers are needed for improved NSCLC management.

Conclusions:

  • Targeting angiogenesis remains a critical therapeutic approach for NSCLC.
  • Investigating the interplay between VEGF, angiogenesis, and tumor immunity is crucial for developing novel treatments.
  • The development of predictive biomarkers for anti-angiogenic therapies will optimize patient outcomes in NSCLC.
Keywords:
AngiogenesisNSCLCmonoclonal antibodiessmall moleculestyrosine kinase inhibitors

More Related Videos

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis07:52

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Published on: December 21, 2014

10.5K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

367

Related Concept Videos

Emerging Adulthood01:27

Emerging Adulthood

Jeffrey Arnett's concept of emerging adulthood offers a framework to understand the unique developmental stage between adolescence and full-fledged adulthood, generally from ages 18 to 25. This period is marked by extensive exploration and shifts in identity, relationships, and career choices, a process known in psychology as role experimentation. Emerging adulthood reflects the evolving cultural expectations surrounding adulthood and the dynamic process of personal transformation during...
649
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.7K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Introduction Cardiac Emergencies01:30

Introduction Cardiac Emergencies

Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
316
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.4K